PURPOSE: Mitochondrial encephalopathy (ME) is a rare disorder of energy metabolism. The disease course can roughly be evaluated by clinical findings. The purpose of this study was to evaluate metabolic spectral changes using proton MR spectroscopy (MRS), and to establish a way to monitor ME by neuroimaging. MATERIALS AND METHODS: Proton MRS data were retrospectively reviewed in 12 patients with muscle biopsy-confirmed ME (M : F = 7 : 5, Mean age = 4.8 years). All received 1H-MRS initially and also after a ketogenic diet and mitochondrial disease treatment cocktail (follow up average was 10.2 months). Changes of N-acetylaspartate/ creatine (NAA/Cr) ratio, choline/creatine (Cho/Cr) ratio, and lactate peak in basal ganglia at 1.2 ppm were evaluated before and after treatment. Findings on conventional T2 weighted MR images were also evaluated. RESULTS: On conventional MRI, increased basal ganglia T2 signal intensity was the most common finding with ME (n = 9, 75%), followed by diffuse cerebral atrophy (n = 8, 67%), T2 hyperintense lesions at pons and midbrain (n = 4, 33%), and brain atrophy (n = 2, 17%). Lactate peak was found in 4 patients; 2 had disappearance of the peak on follow up MRS. Quantitative analysis showed relative decrease of Cho/Cr ratio on follow up MRS (p = 0.0058, paired t-test, two-tailed). There was no significant change in NAA/Cr ratio. CONCLUSION: MRS is a useful tool for monitoring disease progression or improvement in ME, and decrease or disappearance of lactate peak and reduction of Cho/Cr fraction were correlated well with improvement of clinical symptoms.
PURPOSE: Mitochondrial encephalopathy (ME) is a rare disorder of energy metabolism. The disease course can roughly be evaluated by clinical findings. The purpose of this study was to evaluate metabolic spectral changes using proton MR spectroscopy (MRS), and to establish a way to monitor ME by neuroimaging. MATERIALS AND METHODS: Proton MRS data were retrospectively reviewed in 12 patients with muscle biopsy-confirmed ME (M : F = 7 : 5, Mean age = 4.8 years). All received 1H-MRS initially and also after a ketogenic diet and mitochondrial disease treatment cocktail (follow up average was 10.2 months). Changes of N-acetylaspartate/ creatine (NAA/Cr) ratio, choline/creatine (Cho/Cr) ratio, and lactate peak in basal ganglia at 1.2 ppm were evaluated before and after treatment. Findings on conventional T2 weighted MR images were also evaluated. RESULTS: On conventional MRI, increased basal ganglia T2 signal intensity was the most common finding with ME (n = 9, 75%), followed by diffuse cerebral atrophy (n = 8, 67%), T2 hyperintense lesions at pons and midbrain (n = 4, 33%), and brain atrophy (n = 2, 17%). Lactate peak was found in 4 patients; 2 had disappearance of the peak on follow up MRS. Quantitative analysis showed relative decrease of Cho/Cr ratio on follow up MRS (p = 0.0058, paired t-test, two-tailed). There was no significant change in NAA/Cr ratio. CONCLUSION:MRS is a useful tool for monitoring disease progression or improvement in ME, and decrease or disappearance of lactate peak and reduction of Cho/Cr fraction were correlated well with improvement of clinical symptoms.
Authors: Katharina Flemming; Stefan Ulmer; Barbara Duisberg; Andreas Hahn; Olav Jansen Journal: AJNR Am J Neuroradiol Date: 2002-09 Impact factor: 3.825
Authors: H S Kim; D I Kim; B I Lee; E K Jeong; C Choi; J D Lee; P H Yoon; E J Kim; S H Kim; Y K Yoon Journal: Yonsei Med J Date: 2001-02 Impact factor: 2.759
Authors: Harald E Möller; Dirk Wiedermann; Gerhard Kurlemann; Thorsten Hilbich; Gerhard Schuierer Journal: Muscle Nerve Date: 2002-04 Impact factor: 3.217
Authors: Saskia Koene; Paul de Laat; Doorlène H van Tienoven; Gert Weijers; Dennis Vriens; Fred C G J Sweep; Janneke Timmermans; Livia Kapusta; Mirian C H Janssen; Jan A M Smeitink Journal: JIMD Rep Date: 2015-05-13
Authors: Rebecca E Anglin; Patricia I Rosebush; Michael D Noseworthy; Mark Tarnopolsky; Alexander M Weber; Noam Soreni; Michael F Mazurek Journal: CMAJ Open Date: 2013-04-26
Authors: Werner Jh Koopman; Julien Beyrath; Cheuk-Wing Fung; Saskia Koene; Richard J Rodenburg; Peter Hgm Willems; Jan Am Smeitink Journal: EMBO Mol Med Date: 2016-04-01 Impact factor: 12.137